Bibliographic information
GuidelineConsolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations
Year of Publication2022
Issuing InstitutionWHO
Recommendation
Maintained
Long-acting injectable cabotegravir may be offered as an additional prevention choice for people at substantial risk of HIV infection, as part of combination prevention approaches
Recommended in favor
Conditional
Certainty of evidence
Moderate
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Guidelines on long-acting injectable cabotegravir for HIV prevention
Year2022
InstitutionWorld Health Organization